Synapse - Works

Results (5608)

Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations

Journal Article

Manley, B. J.; Reznik, E.; Ghanaat, M.; Kashan, M.; Becerra, M. F.; Casuscelli, J.; Tennenbaum, D.; Redzematovic, A.; Carlo, M. I.; Sato, Y.; more...
Urologic Oncology: Seminars and Original Investigations (2019)

Fulltext@MSK | Save

Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival

Journal Article

Xie, W.; Stopsack, K. H.; Drouin, S. J.; Fu, H.; Pomerantz, M. M.; Mucci, L. A.; Lee, G. S. M.; Kantoff, P. W.
Prostate (2019)

Fulltext@MSK | Save

Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions

Review

Lalani, A. K. A.; McGregor, B. A.; Albiges, L.; Choueiri, T. K.; Motzer, R.; Powles, T.; Wood, C.; Bex, A.
European Urology (2019)

Fulltext@MSK | Save

Datasets for the reporting of neoplasia of the testis: Recommendations from the International Collaboration on Cancer Reporting

Review

Berney, D. M.; Comperat, E.; Feldman, D. R.; Hamilton, R. J.; Idrees, M. T.; Samaratunga, H.; Tickoo, S. K.; Yilmaz, A.; Srigley, J. R.
Histopathology (2019)

Fulltext@MSK | Save

Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS)

Meeting Abstract

Xu, C.; Myers, M.; Buonocore, D. J.; Razavi, P.; Shen, R.; Lai, W. C. V.; Smyth, L. M.; Zheng, T.; Ni, A.; Solit, D. B.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors

Meeting Abstract

Wu, J.; Freites-Martinez, A.; Hellmann, M. D.; Rosenberg, J. E.; Motzer, R. J.; Chapman, P. B.; Rizvi, N. A.; Geskin, L. J.; Reed, V. A.; Dusza, S. W.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts)

Meeting Abstract

Wei, X. X.; Lundgren, K.; Teo, M. Y.; Rosenberg, J. E.; Koshkin, V. S.; Grivas, P.; Carril, L.; Castellano, D. E.; Velho, P.; Hahn, N. M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)

Meeting Abstract

Vuky, J.; Balar, A. V.; Castellano, D. E.; O'Donnell, P. H.; Grivas, P.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Hahn, N. M.; De Wit, R.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC)

Meeting Abstract

Voss, M. H.; Novik, J. B.; Hellmann, M. D.; Ball, M.; Hakimi, A. A.; Miao, D.; Margolis, C.; Horak, C.; Wind-Rotolo, M.; De Velasco, G.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis

Meeting Abstract

Voss, M. H.; Kuo, F.; Sanchez, A.; Ostrovnaya, I.; Cheng, Y.; Patel, P.; Marker, M.; Reising, A.; Chan, T. A. T.; Motzer, R. J.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save